Identifikasi Peptida Early Antigen Virus Epstein-Barr (EA-EBV) Sebagai Kandidat Penanda Diagnosis Karsinoma Nasofaring

THEODORA CAROLINE SIHOTANG, Dewi Kartikawati Paramita, S.Si., M.Si., Ph.D;Jajah Fachiroh, S.P. M.Si., Ph.D

2014 | Skripsi | PENDIDIKAN DOKTER

Latar Belakang: Karsinoma nasofaring (KNF) merupakan keganasan pada epitel di area nasofaring. Karsinoma nasofaring WHO tipe III merupakan tipe yang dominan (95%) berkait 100% dengan infeksi virus Epstein-Barr (EBV). Tingginya respon antibodi IgA EBV merupakan karakteristik KNF, diantaranya respon IgA terhadap Early Antigen (EA). Produksi antigen EA dalam bentuk peptida dikembangkan untuk menutupi kelemahan produksi dengan kultur sel. Tujuan: Mengkaji kemampuan 6 peptida sintetik EA dalam membedakan populasi KNF dan sehat. Metode: Penelitian potong lintang dilakukan terhadap populasi KNF (n=20) dan populasi sehat (n=20). Respon IgA terhadap peptida EA-1580 dan EA-1582 (turunan EA-p47/54) dan peptida EA-1579, EA-1101, EA-1102, dan EA-1104 (turunan EA-p138) diamati dengan metode ELISA tidak langsung (indirect elisa). Analisis perbedaan hasil antara populasi sampel sehat dan KNF dilakukan dengan uji Mann-Whitney U dengan angka signifikansi statistik P value <=0.05. Hasil: Hasil uji Mann Whitney U menunjukkan respon IgAEA-1579, IgA-EA-1580, IgA-EA-1582, IgA-EA-1101, IgA-EA-1102, dan IgA-EA-1104 masing-masing menunjukkan hasil p <0.0001 (U=4), p <0,0001 (U=71), p=0,001 (U=83), p=0,253 (U=157), p=0,529 (U=176), dan p=0,002 (U=90). Kesimpulan: Peptida EA-1579, EA-1580 EA-1582, dan EA-1104 memiliki kemampuan untuk membedakan respon IgA terhadap antigen EA peptida antara populasi sehat dan populasi KNF.

Background: Nasopharyngeal cancer (NPC) is malignancy originating in the mucosa area of the nasopharynx. Nasopharyngeal cancer type WHO III is the dominant type (95%) of all NPC cases in Indonesia and is related ~100% to Epstein-Barr Virus (EBV) infection. Antibody IgA response to EBV is the hallmark of NPC, one of is IgA response to EA proteins. Synthetic peptides derived from EA proteins aiming to replace the use of the EA-EBV natural antigen. Aim: To identify 6 EA synthetic peptides potential to differentiate healthy and NPC. Method: A cross-sectional study was conducted, which included NPC (n=20) and healthy (n=20) sample populations. Sample was collected and tested using indirect ELISA to observe IgA response to EA-1580 and EA-1582 (derived from p47/54 protein sequence), EA-1579, EA-1101, EA-1102, and EA-1104 (derived from p138 protein sequence) peptides. Statistics analysis were performed using Mann-Whitney U test with p<=0.05 significance. Result: Mann-Whitney U test showed IgA-EA-1579, IgA-EA-1580, IgA-EA-1582, IgA-EA-1101, IgA-EA-1102, and IgA-EA-1104 response showed a p value of p <0.0001 (U=4), p <0,0001 (U=71), p=0,001 (U=83), p=0,253 (U=157), p=0,529 (U=176), and p=0,002 (U=90). Conclusion: Early antigen (EA)-1579, -1580, -1582, and -1104 have the ability to differentiate healthy and NPC population.

Kata Kunci : karsinoma nasofaring (KNF), virus EpsteinBarr (EBV), early antigen (EA), IgA, peptida, p47/54, p138